Ultragenyx - Asset Resilience Ratio
Ultragenyx (RARE) has an Asset Resilience Ratio of 13.21% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Ultragenyx debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Ultragenyx's Asset Resilience Ratio has changed over time. See cash generation quality of Ultragenyx to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Ultragenyx's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Ultragenyx.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $167.00 Million | 13.21% |
| Total Liquid Assets | $167.00 Million | 13.21% |
Asset Resilience Insights
- Moderate Liquidity: Ultragenyx has 13.21% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Ultragenyx Industry Peers by Asset Resilience Ratio
Compare Ultragenyx's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 0.91% |
|
Nanobiotix S.A
PA:NANO |
Biotechnology | 53.40% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 68.30% |
Annual Asset Resilience Ratio for Ultragenyx (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Ultragenyx.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.91% | $259.00 Million | $1.53 Billion | -12.11pp |
| 2024-12-31 | 29.02% | $436.30 Million | $1.50 Billion | +4.63pp |
| 2023-12-31 | 24.39% | $363.62 Million | $1.49 Billion | -15.39pp |
| 2022-12-31 | 39.78% | $614.82 Million | $1.55 Billion | +11.37pp |
| 2021-12-31 | 28.42% | $432.61 Million | $1.52 Billion | +0.68pp |
| 2020-12-31 | 27.73% | $488.01 Million | $1.76 Billion | -0.59pp |
| 2019-12-31 | 28.33% | $321.65 Million | $1.14 Billion | -19.80pp |
| 2018-12-31 | 48.12% | $346.27 Million | $719.56 Million | +20.82pp |
| 2017-12-31 | 27.31% | $134.00 Million | $490.75 Million | -13.21pp |
| 2016-12-31 | 40.51% | $219.03 Million | $540.63 Million | -20.86pp |
| 2015-12-31 | 61.37% | $343.43 Million | $559.57 Million | -21.05pp |
| 2014-12-31 | 82.42% | $163.16 Million | $197.97 Million | +5.39pp |
| 2013-12-31 | 77.03% | $45.95 Million | $59.65 Million | -- |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more